U.S. persons/entities who paid or reimbursed for Branded or authorized generic EpiPens for consumption (not resale) between August 24, 2011 and November 1, 2020; plus persons/entities in 17 Antitrust States who paid/reimbursed for Branded EpiPens between January 28, 2013 and November 1, 2020. Notable exclusions apply (government entities, fully insured health plans, certain flat co-pay consumers, Medicaid purchasers, PBMs).
